Oncolytics Reolysin study shows 88% disease control Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncolytics Reolysin study shows 88% disease control

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: bcjt	1/10/2011 9:06:39 AM
	of 3

Oncolytics starts Reolysin study with Folfiri Oncolytics Biotech Inc (C:ONC) Shares Issued 67,842,669 Last Close 1/7/2011 $6.26 Monday January 10 2011 - News Release Dr. Brad Thompson reports ONCOLYTICS BIOTECH INC. ANNOUNCES OPENING OF ENROLLMENT IN U.S. PHASE I COLORECTAL CANCER STUDY Oncolytics Biotech Inc.'s U.S. phase I study of Reolysin in combination with Folfiri (folinic acid (leucovorin) plus Fluorouracil (5-FU) plus Irinotecan) in patients with oxaliplatin refractory/intolerant Kras mutant colorectal cancer (REO 022) is now open to enrolment. The principal investigator is Dr. Sanjay Goel of the Montefiore Medical Center at The Albert Einstein College of Medicine in New York. "We continue to advance REOLYSIN into clinical testing in new indications where we believe the product may have sound clinical and commercial potential," said Dr. Brad Thompson, President and CEO of Oncolytics. "We are focusing our clinical program increasingly to look at patients with Kras mutant cancers by either pre-screening patients for Kras status, as in the case of this study and the Phase II trial we are running in non-small cell lung cancer (REO 016), or by selecting indications with widespread Kras involvement, such as our ongoing Phase II study in advanced pancreatic cancer (REO 017)." The trial is a Phase I dose escalation study with three dose levels, comprising cohorts of three to six patients, to determine a maximum tolerated dose and dose-limiting toxicities with the combination of REOLYSIN and FOLFIRI. FOLFIRI will be administered on the first day of a two week (14-day) cycle, while REOLYSIN will be administered on days one through five of a four week (28-day) cycle. Eligible patients include those with histologically confirmed cancer of the colon or rectum with Kras mutation and measurable disease. They must have progressed on or within 190 days after last dose of oxaliplatin regimen as front-line therapy in the metastatic setting or be intolerant to oxaliplatin. The study is expected to enroll 12 to 20 patients. The rationale for conducting the study is based on signals of efficacy seen in a range of preclinical and clinical work with REOLYSIN. This includes a National Cancer Institute screen of seven colorectal cancer cell lines (four with ras mutations), all of which were susceptible to REOLYSIN; preclinical research into the efficacy of REOLYSIN in combination with various chemotherapeutic agents in colorectal cancer cell lines; observation of CEA responses and stable disease in colorectal patients in a phase I study of REOLYSIN as a monotherapy; and interim results from a translational study with REOLYSIN as a monotherapy that is currently ongoing, which showed evidence of viral replication and tumour cell death in four of six patients with metastatic colorectal cancer analyzed to date, two of which had confirmed Kras mutations in codon 12. We seek Safe Harbor. 2011 Canjex Publishing Ltd.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next